Invesco Dow Jones Industrial Average Dividend ETF
Will IBM’s New Hoard of Data Affect Bias in Facial Recognition?
Yesterday, IBM (IBM) released a hoard of data of 1 million facial images obtained from a Flickr dataset of 100 million photos and videos.
Caterpillar: Analysts’ Recommendations
Among the 29 analysts tracking Caterpillar, 62% recommended a “buy,” 34% recommended a “hold,” and 4% recommended a “sell.”
What Drove Caterpillar’s Construction Industries Segment in Q3?
Caterpillar’s (CAT) Construction Industries segment is the company’s biggest revenue contributor.
Caterpillar: More Analysts Favor a ‘Buy’
Analysts’ interest in Caterpillar has increased since its Q2 2018 earnings—60% recommend a “buy,” 33% recommend a “hold,” and 7% recommend a “sell.”
3M’s Valuations Compared to Its Peers
3M is trading at a higher multiple than its peers. 3M’s valuations corrected after it made a downward revision to its fiscal 2018 EPS.
Caterpillar’s Construction Industries Segment in Q2 2018
Caterpillar’s Construction Industries segment was the company’s most significant revenue contributor in the second quarter.
Why Analysts Don’t See Much Upside for 3M
There weren’t any changes in the number of analysts tracking 3M or their recommendations after 2018 earnings.
Where Is Walmart’s Dividend Yield Heading?
Walmart’s (WMT) net sales rose 2% in 2015 before falling 1% in 2016.
Why UTX’s Dividend Yield Is on a Downward Trajectory
United Technologies (UTX) posted 2% net sales growth in 2016 after a 3% decline in 2015, as costs remained relatively uniform.
Why Does Visa Have an Inverted V-Shaped Dividend Yield Curve?
Visa’s (V) revenue rose 9% in 2016 compared to 9.3% in 2015.
Why Walt Disney’s Dividend Yield Curve Is Sloping Upwards
Walt Disney (DIS) posted 6% revenue growth in 2016 compared to almost 8% growth in 2015.
How Does 3M’s Dividend Yield Curve Look?
3M has recorded a 3.0% revenue growth in the first half of 2017, driven by growth in every segment and flat growth in the consumer segment.
Exploring Keytruda, Merck’s Immuno-Oncology Blockbuster
In the last few articles, we’ve discussed Merck & Co.’s (MRK) major product developments. Keytruda is one of the key products in Merck’s immuno-oncology portfolio.